Venetoclax (VEN) is a potent oral inhibitor of the anti-apoptotic molecule BCL2, used to treat adults with chronic lymphocytic leukemia (CLL), in association with obinutuzumab in patients who have not previously been treated or with rituximab in patients who have received at least one previous treatment [1]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.